Skip to main content

Page last checked

Research compound · not FDA-approved

DSIP

Also called delta sleep-inducing peptide or delta sleep peptide.

DSIP stands for delta sleep-inducing peptide. It is nine amino acids long, and it was recovered in 1977 from the blood of rabbits put into deep sleep electrically.

What matters first

Why people look it up
It is sold for insomnia and for deeper sleep.
What the evidence shows
It has more human research than many peptides sold this way, but the evidence is still thin. European groups gave it during the 1980s to people with insomnia and to people in alcohol and opiate withdrawal, and reported improved sleep. The studies were small, mostly open label, used intravenous dosing and never led to an approval.
Dose status
DSIP is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Evidence snapshot

Foreign approval or limited human data

The fastest way to see what kind of evidence this page is built on.

Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study2 reported dose rows
Safety evidence
1 listed safety findingCommon and serious effects shown apart
Sources
3 cited sourcesMedical review complete · 2026-08-12
Open the shareable evidence image
DSIP at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Further down: research and dosing details · how good the evidence is · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-12open the primary sources

What is known about DSIP

DSIP, delta sleep-inducing peptide, is a nine-amino-acid sequence recovered in 1977 from the cerebral venous blood of rabbits during electrically induced slow-wave sleep. European groups injected it into people with insomnia and into people in alcohol and opiate withdrawal through the 1980s, at doses of 25 to 30 nanomoles per kilogram, and reported sleep normalizing. Those human studies are small, largely uncontrolled, forty years old and never led to an approval.

DSIP research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
TopicValue
Strongest sourcelimited human data
FDA approvalNot FDA-approved
Studied dosing21.2 mcg as a single dose before sleep, per kilogram of body weight (published as 25 nmol/kg; two small insomnia studies reported improved sleep on it) — from clinical trials
Studied dosing25.5 mcg per kilogram of body weight, six doses across one week (published as 30 nmol/kg; a sleep-laboratory study of 18 chronic insomniacs aged 29 to 83, with the effect tracked for a further week afterwards) — from clinical trials
Typical vials5 mg · 10 mg

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

DSIP dosage chart: what the human studies used

The human DSIP literature stated amounts in nanomoles per kilogram. The mass conversions below keep that per-kilogram basis and do not assume a body weight.

These are quantities given in small 1980s studies, not an approved dose and not an under-the-skin schedule.

DSIP dosage chart: what the human studies used. These are quantities given in small 1980s studies, not an approved dose and not an under-the-skin schedule.
Study recordPublished amountMass conversionRoute and scheduleWho was studied
1984 insomnia investigations25 nmol/kg21.2 mcg/kgIntravenous single injection before sleepTwo small insomnia studies summarized together; the PubMed abstract does not state a participant count
1986 sleep-laboratory study30 nmol/kg25.5 mcg/kgIntravenous; six doses across one week18 chronic insomniacs, ages 29–83, followed for one further week

Each row keeps the units and study description used in the cited PubMed article. Read the sources.

What the evidence for DSIP is

People have received this compound in a documented setting, or it has approval outside the United States. The available human evidence is still too limited to show a clear dose-and-result pattern for US use.

limited human data
What it establishes
It shows that people have received it and that some human information exists.
What it does not establish
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.

Where DSIP is in clinical trials

No trial of this compound is registered on ClinicalTrials.gov.

That is worth sitting with. Nobody has registered a study to find out whether DSIP works in people, so no result is coming and no date is worth waiting for. Sellers are not waiting for that work either.

Searched under the name delta sleep-inducing peptide, which is how the registry files it.

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-08-23

Every compound we track, and what stage each one has reached →

Regulatory status

DSIP has an international generic name, emideltide.

FDA listed it for a compounding-committee review on 24 July 2026. It went up as a candidate for the section 503A bulk drug substances list. The uses under review were opioid withdrawal, chronic insomnia and narcolepsy.

Those are the three the 1980s papers examined. That review asks whether pharmacists may compound it at all. It is not an approval.

No company has filed to market it anywhere. Material sold under this name ships for lab research. So what is in the vial rests on a seller’s certificate, not on a standard anyone enforces.

Full regulatory tracker →

Where to go next on DSIP

The schedule, the side effects and the mixing math each have their own page.

Why DSIP carries no boxed warning

7 standing caveats on the DSIP page, written out rather than implied.

Check a DSIP draw against the printed syringe marks

U-100, U-50 and U-40 barrels read differently; the DSIP tool covers all three.

Reconstituting DSIP at 10 mg, step by step

The 10 mg DSIP table itself, not a general rule applied to an unrelated vial size.

Mixing a 5 mg DSIP vial, water volume by water volume

What each bacteriostatic-water volume does to a 5 mg DSIP vial, in mg/mL and units.

What backs the DSIP numbers, and what backs the rest

Every row states whether a label, a trial or nothing stands behind it, including DSIP

Who else is sold for sleep besides DSIP

What people take it for and what the sleep page shows stay in separate columns, including DSIP

Every calculator on this site, DSIP and the rest

Every intermediate value is printed, for DSIP or any other vial.

Where the DSIP program has actually got to

A registration is a plan and never gets reported as a result, with DSIP as context

Primary regulatory documents, including DSIP

Every URL was fetched and live on its retrieval date, DSIP or otherwise.

All the pages DSIP is compared with

The spine every dosing, safety and calculator page reads from, including DSIP

Safety notes

  • The human doses on this page are per kilogram of body weight and were given intravenously — this site models subcutaneous injection, which is not the route any of this evidence used
  • No controlled trial has established that this peptide induces sleep; the supporting studies are small, mostly open-label, and were published in the 1980s
  • The largest human series enrolled 107 people and measured clinician and nursing impressions of withdrawal symptoms, not sleep architecture
  • The 1977 isolation work was done in rabbits — the name describes an experiment, not an effect shown in people
  • Nothing in this literature was replicated into an approval: no regulator anywhere has licensed the peptide
  • FDA listed it, under its nonproprietary name emideltide, for compounding-committee review on 24 July 2026; the outcome of that review is not reflected in this record
  • Sold for laboratory research only, with no enforced standard governing vial contents

Questions about DSIP

Is DSIP FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is DSIP taken?

By a drip or injection into a vein, as a single dose before sleep, per kilogram of body weight.

How does DSIP differ from the other compounds in this class?

DSIP has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.

What is not known about DSIP?

It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

Questions readers ask

What are the benefits of taking DSIP peptide?

None have been established, though there is more human evidence here than for most peptides sold this way. European groups injected it into insomniacs and into people withdrawing from alcohol and opiates through the 1980s, and reported sleep normalizing.

That literature is small, largely open-label, forty years old, and no regulator anywhere licensed it afterwards. No controlled trial has established that the peptide induces sleep.

How long does it take for DSIP to kick in?

No published study reports an onset time. The single-dose work gave it before sleep and read out sleep quality, not the minutes between injection and effect.

The sleep-laboratory study dosed eighteen chronic insomniacs six times across one week, then followed them a further week. That is a schedule, not a measure of how quickly anything starts.

What are the side effects of DSIP?

Headache is the only one this literature reports. It comes from the largest human series, 107 inpatients treated during alcohol or opiate withdrawal. That report describes things going well there apart from headache in a few people.

Nobody published an incidence figure for it, and no other reaction appears on the page. Studies this small, this old and this uncontrolled are not where uncommon harms show up.

Where do you inject DSIP peptide?

Every human dose in this literature went into a vein, in a hospital. Vials sold under this name serve an injection under the skin, which is not the route any of that evidence used.

The gap matters more than it sounds. A quantity set for a vein does not carry across to a different route. All of these were set per kilogram of body weight as well.

3primary sources, each with the day we read it — open the documents used on this page